噻托溴铵粉吸入剂联合小剂量阿奇霉素治疗支气管扩张症疗效观察被引量：12

在线阅读下载PDF

导出

摘要支气管扩张症是指感染、理化、免疫等原因引起的支气管壁肌肉和弹力支撑组织的破坏而引起的支气管病理性扩张,表现为慢性咳嗽、大量脓痰、反复咯血。由于气道慢性炎症反应,导致气道高反应性和气流阻塞,出现呼吸困难、发绀、杵状指等。急性加重期短程的抗生素治疗能有效控制感染,但对慢性气道炎症影响较小。近年研究表明,大环内酯类抗生素不仅有抗感染作用,还能减轻气道炎症反应及免疫活性,对反复发作的支气管扩张有一定治疗作用。

作者周华娟刘明

机构地区杭州市余杭区第五人民医院呼吸科

出处《浙江中西医结合杂志》 2015年第5期453-455,共3页 Zhejiang Journal of Integrated Traditional Chinese and Western Medicine

基金杭州市余杭区科技计划项目(No.2014-18)

关键词支气管扩张症噻托溴铵粉吸入剂阿奇霉素

分类号 R562.22 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献11

1IpM,Shum D,Lauder I,et al.Effect of antibiotics on stupum inflammatory contents in acute exacerbations of bronchiec- tasis[ J ].Respir Med, 1993,87 (6) : 449-454.
2曾军.大环内酯类抗生素在支气管扩张症中的应用[J].中国呼吸与危重监护杂志,2007,6(3):166-168. 被引量：11
3宋成峰,黄信刚.噻托溴铵治疗慢性呼吸道疾病的研究进展[J].医学综述,2012,18(6):909-911. 被引量：8
4Celli BR, MacNee W.ATS/ERS Task Force.Standards for the diagnosis and treatment of patients with COPD:asummary of the ATS /ERS position paper[J].Eur RespirJ,2004,23 (6) : 932-946.
5侯刚,李朋,李文扬,尹燕,王晓慧,韩丹,康大海,王秋月,康健.稳定期中重度慢性阻塞性肺疾病患者运动性低氧的发生情况及危险因素研究[J].中国全科医学,2013,16(25):2948-2950. 被引量：17
6Kim DN, Lazarus AA.Management of bronchiectasis[J ].Dis- Mon, 2008,54( 8 ) : 540-546.
7Serisier DJ, Martin ML.Long-tom,low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations [ J ].Respir Med, 2011,105 ( 6 ) : 946-949.
8顾晓花,沈策.长期小剂量阿奇霉素治疗支气管扩张症的疗效观察[J].中国感染与化疗杂志,2010,10(1):38-40. 被引量：35
9Koh YY,Lee MH,Sun YH,et al.Effect of roxithromycin on airway responsiveness in children with bronchiectasis:a double-blind,placebo-controlled study[J].Eur Respir J, 1997,10(5 ) : 994-999.
10Troosters T,Celli B,Lystig T,et al.Tiotropium as a first maintenance drug in COPD:secondary analysis of the UP- LIFT trial[J].EUR Respir J,2010,36( 1 ):65-73.

二级参考文献68

1胡克,杨炯,陈雪芹.支气管扩张症患者对沙丁胺醇与溴化异丙托品的反应性[J].中国呼吸与危重监护杂志,2004,3(5):304-307. 被引量：17
2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量：8245
3Alzeer AH,Masood M,Basha SJ,et al.Survival of bronchiectatic patients with respiratory failure in ICU[J].BMC Pulm Med,2007,7 (17):17-23.
4Kim DN,Lazarus AA,Management of bronchiectasis[J].Dis Mon,2008,54(8):540-546.
5Shoemark A,Ozerovitch L,Wilson R.Aetiology in adult patients with bronchiectasis[J].Resp Med,2007,101(6):1163-1170.
6Martinez-Garcia MA,Perpina-Tordera M,Roman-Sanchez P,et al.Quality-of-life determinants in patients with clinically stable bronchiectasis[J].Chest.2005,128(2):739-745.
7Mizukane R,Hirakata Y,Kaku M,et al.Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa[J].Antimicrob Agents Chemother,1994,38(3):528-533.
8Mitsuya Y,Kawai S,Kobayashi.H.Influence of macrolides on guanosine diphospho-D-mannose dehydrogenase activity in Pseudomonas biofilm[J].J Infect Chemotherapy,2000,6 (1):45-50.
9Wozniak DJ,Keyser R.Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa[J].Chest,2004,125(2 Suppl):62S-69S.
10Shinkai M,Lopez-Boado YS,Rubin BK.Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin[J].J Antimicrob Chemother,2007,59 (6):1096-1101.